FDA reviewers voice concern about side effects of belatacept

02/25/2010 | Los Angeles Times (tiered subscription model)

Bristol-Myers Squibb's kidney transplant drug belatacept extended survival better than older treatments, FDA reviewers said, but it also appeared to cause a higher rate of severe kidney rejection and neurological disease. A panel of experts is scheduled to evaluate the drug's safety and efficacy next week.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park